Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
1B) indicated that in the NCD group, the kidneys were more echogenic than the liver, whereas in the HFD group, the liver echogenicity was notably higher than that in the kidneys
The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings
J Gastroenterol Hepatol 2006
Some aspects of the research appear promising, while others remain unproven: What appears promising so far: Reduced substance-seeking behavior observed in animal models Anecdotal and observational reports of decreased cravings in some individuals Growing scientific interest in shared reward pathways between appetite and addiction What remains unproven or unclear: Whether observed effects lead to sustained recovery outcomes How GLP-1s affect the psychological and social dimensions of addiction Whether benefits, if present, are consistent across substances or populations Differences in study design also limit interpretation: Animal trials do not reliably predict human outcomes Observational data cannot establish causation Controlled human trials remain small, limited, and inconsistent Safety considerations are equally important and must be weighed carefully: Common side effects include nausea, appetite suppression, and gastrointestinal distress Changes in appetite or weight may interact with existing mental health symptoms For individuals with eating disorders, appetite-suppressing effects may pose particular risks Given these uncertainties, GLP-1 medications should not replace evidence-based addiction treatments
Yes, when administered by a trained medical professional, dermal fillers may help reduce the appearance of wrinkles by adding volume to targeted areas
